Genus vs. Species: How Broad Are the Anti-VEGF Antibody Claims, Really?

The claim-construction question that decides anti-VEGF disputes is breadth. At the broad end, Genentech's US9777059B2, "Anti-VEGF antibodies" (issued October 3, 2017; CPC C07K 16/22), claims antibodies defined by their binding to vascular endothelial growth factor and by complementarity-determining-region (CDR) features. At the narrow end, SinoCellTech's US12060416B2, "Humanized anti-VEGF monoclonal antibody" (2024), and US12479911B2, "Humanized anti-VEGF antibody Fab fragment" (2025), claim specific humanized sequences. Same target, very different claim scope.

Genus claims describe a category — antibodies that bind VEGF with defined functional or structural features — and aim to capture many embodiments. Species claims describe one molecule precisely. The genus claim is powerful if it holds, because it can read on competitors who never saw the patentee's exact antibody; it is also fragile, because written-description and enablement doctrine demand that the specification actually teach the full claimed genus, not just one example. Post-Amgen v. Sanofi, that demand is sharper than ever.

The CDR limitations are where construction gets technical. Many anti-VEGF claims recite specific CDR sequences; a defendant's antibody either has those CDRs (or equivalents) or it does not. A Fab-fragment claim like US12479911B2 narrows further to the antigen-binding fragment rather than the full immunoglobulin, which matters for products engineered as fragments. Reading the limitation precisely — full antibody versus Fab, exact CDRs versus functional binding — tells you whether a given biosimilar even arguably reads on the claim.

The Genentech grants matter as the field's anchor because Genentech is, by a wide margin, the largest anti-VEGF assignee in the patent record, with Regeneron and Novartis also holding substantial estates. A field with one dominant early assignee and many later species filers is the classic setup for genus-versus-species litigation: the pioneer asserts breadth, the followers argue their specific sequence is outside it or that the broad genus is invalid for want of adequate description.

For a biosimilar or follow-on developer, the freedom-to-operate read is a two-step. First, does your antibody fall within any live broad genus claim — judged on binding plus claimed structural features? Second, if you cleared the genus, do you separately read on any narrow species claim covering a sequence close to yours? Clearing one does not clear the other, and the species filings keep accumulating, narrowing the practical white space even where the broad genus is contestable.

The disciplined conclusion: "anti-VEGF antibody patent" is not one thing. It is a spectrum from genus to species, and claim construction — what the independent claim actually recites about binding, CDRs, and antibody format — determines both infringement reach and invalidity exposure. Describe the asserted claim by where it sits on that spectrum, not by the drug it is associated with.